NCT06282991View on ClinicalTrials.gov

A Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer Which Could Not Be Controlled

CompletedOBSERVATIONAL
Enrollment

73

Participants

Timeline

Start Date

July 22, 2020

Primary Completion Date

January 18, 2021

Study Completion Date

January 18, 2021

Conditions
Non-Small Cell Lung Carcinoma
Interventions
DRUG

Lorlatinib

ALK/ROS1 tyrosine kinase inhibitor

Trial Locations (6)

100

National Taiwan University Hospital, Taipei

333

Chang Gung Memorial Hospital - Linkou Branch, Taoyuan

402

Chung Shan Medical University Hospital, Taichung

11217

Taipei Veterans General Hospital, Taipei

83301

CHANG GUNG MEMORIAL HOSPITAL Kaohsiung Branch, Kaohsiung City

407219

Taichung Veterans General Hospital, Taichung

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT06282991 - A Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer Which Could Not Be Controlled | Biotech Hunter | Biotech Hunter